Skip to main content
AmigoFish

Episode 502: AUA 2026 and FDA bladder cancer meeting

From The Uromigos · · 35 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on Deltalimagene, a non-viral gene therapy. The conversation highlights the complexities of treatment options, the need for robust clinical trials, and the future landscape of bladder cancer therapies

Back to The Uromigos · Report a problem